Cholestyramine could be a Good Choice for Difficult Control Type 2 Diabetes on Optimal Oral Therapy

Abstract

Introduction: Type 2 diabetes mellitus (T2DM) poses a significant challenge when optimal oral therapies fail to achieve adequate glycemic control. This study explores the potential of cholestyramine, a bile acid sequestrant traditionally used for lowering cholesterol, as an auxiliary therapy for patients with T2DM on maximized oral medication regimens.

Despite the effectiveness of various oral medications, some individuals with T2DM experience persistent hyperglycemia.

Cholestyramine's mechanism of action in T2DM management still needs to be fully elucidated. While its primary function is to bind bile acids in the intestine, potentially improving glp1 secretion, more research is required to understand the specific pathways involved in glycemic control.

Materials and methods: 200  patients with difficulty treating type 2 diabetes on optimal oral therapy. One hundred patients received cholestyramine as a treatment of hypercholesterolemia with optimal oral therapy. All patients underwent an hba1c and total cholesterol tests every three months, recorded on the electronic system.

Results: The results show a statistically significant difference in hba1c in group 1 patients before and after three months of treatment with cholestyramine with a p-value less than 0.0001.

Conclusion: This review investigates the possibility of cholestyramine as an additional treatment option for individuals with T2DM struggling to achieve glycemic control despite optimized oral therapies. By analyzing existing research and highlighting areas for further investigation, this review aims to contribute to the ongoing exploration of novel therapeutic approaches in T2DM management.